0001012975-20-000601.txt : 20200701
0001012975-20-000601.hdr.sgml : 20200701
20200701161436
ACCESSION NUMBER: 0001012975-20-000601
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200630
FILED AS OF DATE: 20200701
DATE AS OF CHANGE: 20200701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pivotal bioVenture Partners Fund I, L.P.
CENTRAL INDEX KEY: 0001695076
STATE OF INCORPORATION: E9
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39343
FILM NUMBER: 201005506
BUSINESS ADDRESS:
STREET 1: 501 SECOND STREET, SUITE 200
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
BUSINESS PHONE: (345) 949 1040
MAIL ADDRESS:
STREET 1: 501 SECOND STREET, SUITE 200
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
FORMER NAME:
FORMER CONFORMED NAME: Pivotal Venture Partners Fund I, L.P.
DATE OF NAME CHANGE: 20170118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pivotal bioVenture Partners Fund I G.P., L.P.
CENTRAL INDEX KEY: 0001752862
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39343
FILM NUMBER: 201005507
BUSINESS ADDRESS:
STREET 1: 501 SECOND STREET, SUITE 200
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
BUSINESS PHONE: (415) 697-1002
MAIL ADDRESS:
STREET 1: 501 SECOND STREET, SUITE 200
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akouos, Inc.
CENTRAL INDEX KEY: 0001722271
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 645 SUMMER STREET, SUITE 200
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-245-5715
MAIL ADDRESS:
STREET 1: 645 SUMMER STREET, SUITE 200
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-06-30
1
0001722271
Akouos, Inc.
AKUS
0001695076
Pivotal bioVenture Partners Fund I, L.P.
501 SECOND STREET, SUITE 200
SAN FRANCISCO
CA
94107
0
0
1
0
0001752862
Pivotal bioVenture Partners Fund I G.P., L.P.
501 SECOND STREET, SUITE 200
SAN FRANCISCO
CA
94107
0
0
1
0
Common Stock
2020-06-30
4
C
0
1499971
A
1499971
I
See footnote
Common Stock
2020-06-30
4
P
0
294117
17.00
A
1794088
I
See footnote
Series B Preferred Stock
2020-06-30
4
C
0
1499971
0
D
Common Stock
1499971
0
I
See footnote
On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., or Pivotal GP. Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal and may be deemed to have shared voting and dispositive power over the shares owned by Pivotal.
/s/ Heather Preston, MD - for Pivotal bioVenture Partners Fund I, L.P., as Managing Partner
2020-07-01
/s/ Heather Preston, MD - for Pivotal bioVenture Partners Fund I G.P., L.P., as Managing Partner
2020-07-01